Engineers Gate Manager’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Engineers Gate Manager’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,650	Closed	-$393K	–	2380
2022 Q1	$393K	Buy	+14,650	New	+$492K	0.02%	1206
2021 Q4	–	Sell	-10,435	Closed	-$693K	–	2387
2021 Q3	$693K	Buy	+10,435	New	+$743K	0.04%	693
2021 Q2	–	Sell	-9,500	Closed	-$899K	–	2177
2021 Q1	$899K	Buy	+9,500	New	+$1.13M	0.04%	637

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Engineers Gate Manager's TPTX Position: Q2 2022 in Review

Engineers Gate Manager sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 14,650 shares — an estimated $393K sold.

Engineers Gate Manager first reported a position in TPTX in Q1 2021 and held it in 3 quarters. The position peaked at $899K in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Engineers Gate Manager reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Engineers Gate Manager sold 14,650 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $393K.
Engineers Gate Manager first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Engineers Gate Manager's Turning Point Therapeutics, Inc. Common Stock position peaked at $899K in Q1 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Engineers Gate Manager's 13F filing for Q2 2022, filed 15 Aug 2022.